ALK Gene RearrangementPhase 3NCT02201992
Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial)
A Phase 3 study testing Clinical Observation, Crizotinib and Laboratory Biomarker Analysis in people with ALK Gene Rearrangement and ALK Gene Translocation, run by ECOG-ACRIN Cancer Research Group at 1,618 sites in 3 countries.
Trial summary
This randomized phase III trial studies how well crizotinib works in treating patients with stage IB-IIIA non-small cell lung cancer that has been removed by surgery and has a mutation in a protein called anaplastic lymphoma kinase (ALK). Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- ALK Gene Rearrangement, ALK Gene Translocation, ALK Positive
- What is being tested?
- Clinical Observation, Crizotinib and Laboratory Biomarker Analysis
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 166 participants
- Where
- 1,618 sitesin 3 countries
- Study dates
- 23 Mar 2015to 1 May 2036
- Phase
- Phase 3
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Patients must have undergone complete surgical resection of their stage IB (>= 4 cm), II, or non-squamous IIIA NSCLC per American Joint Committee on Cancer (AJCC) 7th edition and have had negative margins; N3 disease is not allowed
- Baseline chest computed tomography (CT) with or without contrast must be performed within 6 months (180 days) prior to randomization to ensure no evidence of disease; if clinically indicated additional imaging studies must be performed to rule out metastatic disease
- Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1
- Patients must be registered to the ALCHEMIST-SCREEN (ALLIANCE A151216) trial prior to randomization
- Positive for translocation or inversion events involving the ALK gene locus (e.g. resulting in echinoderm microtubule associated protein like 4 [EML4]-ALK fusion) as determined by the Vysis Break Point fluorescence in situ hybridization (FISH) assay and defined by an increase in the distance between 5? and 3? ALK probes or the loss of the 5? probe; this must have been performed:
- By a local Clinical Laboratory Improvement Amendments (CLIA) certified laboratory: report must indicate the results as well as the CLIA number of the laboratory which performed the assay; tissue must be available for submission for central, retrospective confirmation of the ALK fusion status via ALCHEMIST-SCREEN (ALLIANCE A151216) OR
Show all 33Show fewer
- Patient registered to and the ALK fusion status performed centrally on the ALCHEMIST-SCREEN (ALLIANCE A151216)
- Women must not be pregnant or breast-feeding
- All females of childbearing potential must have a blood or urine pregnancy test within 72 hours prior to randomization to rule out pregnancy; a female of childbearing potential is any woman, regardless of sexual orientation or whether they have undergone tubal ligation, who meets the following criteria: 1) has not undergone a hysterectomy or bilateral oophorectomy; or 2) has not been naturally postmenopausal for at least 24 consecutive months (i.e., has had menses at any time in the preceding 24 consecutive months)
- Women of childbearing potential and sexually active males must be strongly advised to practice abstinence or use an accepted and effective method of contraception
- Patients must NOT have uncontrolled intercurrent illness including, but not limited to, serious ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, uncontrolled cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
- No known interstitial fibrosis or interstitial lung disease
- No prior treatment with crizotinib or another ALK inhibitor
- No ongoing cardiac dysrhythmias of grade >= 2 National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0, uncontrolled atrial fibrillation (any grade), or corrected QT (QTc) interval > 470 msec
- No use of medications, herbals, or foods that are known potent cytochrome P450, subfamily 3A, polypeptide 4 (CYP3A4) inhibitors or inducers, included but not limited to those outlined
- Patients must be adequately recovered from surgery at the time of randomization
- The minimum time requirement between date of surgery and randomization must be at least 4 weeks (28 days)
- The maximum time requirement between surgery and randomization must be:
- 3 months (90 days) if no adjuvant chemotherapy was administered
- 8 months (240 days) if adjuvant chemotherapy was administered
- 10 months (300 days) if adjuvant chemotherapy and radiation therapy were administered
- Patients must have completed any prior adjuvant chemotherapy or radiation therapy 2 or more weeks (6 or more weeks for mitomycin and nitrosoureas) prior to randomization and be adequately recovered at the time of randomization
- NOTE: Patients taking low dose methotrexate for non-malignant conditions and other cytotoxic agents for non-malignant conditions are allowed to continue treatment while on study
- NOTE: Neo-adjuvant chemotherapy or radiation therapy for the resected lung cancer is not permitted
- Serum aspartate aminotransferase (AST) and serum alanine aminotransferase (ALT) =< 2.5 x upper limit of normal (ULN)
- Total serum bilirubin =< 1.5 x ULN
- Absolute neutrophil count (ANC) >= 1500/mm^3
- Platelets >= 30,000/mm^3
- Hemoglobin >= 8.0 g/dL
- Serum creatinine =< 2 x ULN
- Prior to randomization patients with any non-hematologic toxicity from surgery, chemotherapy, or radiation must have recovered to grade =< 1 with the exception of alopecia and the criteria outlined
- Patients must not have any history of locally advanced or metastatic cancer requiring systemic therapy within 5 years from randomization, with the exception of in-situ carcinomas and non-melanoma skin cancer; patients must have no previous primary lung cancer diagnosed concurrently or within the past 2 years
- Patients may not be receiving any other investigational agents while on study
Who cannot join
None listed.
Trial locations and contacts
1,618 sites in 3 countries.
305 sites in 3 countries
United States300 sites
Hawaii Cancer Care - Savio
‘Aiea, Hawaii, 96701
Pali Momi Medical Center
‘Aiea, Hawaii, 96701
Queen's Cancer Center - Pearlridge
‘Aiea, Hawaii, 96701
Straub Pearlridge Clinic
‘Aiea, Hawaii, 96701
The Cancer Center of Hawaii-Pali Momi
‘Aiea, Hawaii, 96701
The Queen's Medical Center - West Oahu
‘Ewa Beach, Hawaii, 96706
Providence Regional Cancer System-Aberdeen
Aberdeen, Washington, 98520
Hendrick Medical Center
Abilene, Texas, 79601
Hickman Cancer Center
Adrian, Michigan, 49221
Riverwood Healthcare Center
Aitkin, Minnesota, 56431
Cleveland Clinic Akron General
Akron, Ohio, 44307
Phoebe Putney Memorial Hospital
Albany, Georgia, 31701
Lovelace Medical Center-Downtown
Albuquerque, New Mexico, 87102
Lovelace Medical Center-Saint Joseph Square
Albuquerque, New Mexico, 87102
University of New Mexico Cancer Center
Albuquerque, New Mexico, 87102
Hematology Oncology Associates
Albuquerque, New Mexico, 87106
New Mexico Oncology Hematology Consultants
Albuquerque, New Mexico, 87109
Presbyterian Kaseman Hospital
Albuquerque, New Mexico, 87110
Christus Saint Frances Cabrini Hospital
Alexandria, Louisiana, 71301
Lehigh Valley Hospital-Cedar Crest
Allentown, Pennsylvania, 18103
Saint Luke's Cancer Center - Allentown
Allentown, Pennsylvania, 18104
Aultman Alliance Community Hospital
Alliance, Ohio, 44601
MyMichigan Medical Center Gratiot
Alma, Michigan, 48801
MyMichigan Medical Center Alpena
Alpena, Michigan, 49707
AdventHealth Altamonte
Altamonte Springs, Florida, 32701
Saint Anthony's Health
Alton, Illinois, 62002
UPMC Altoona
Altoona, Pennsylvania, 16601
The Don and Sybil Harrington Cancer Center
Amarillo, Texas, 79106
American Fork Hospital / Huntsman Intermountain Cancer Center
American Fork, Utah, 84003
Mary Greeley Medical Center
Ames, Iowa, 50010
McFarland Clinic PC - Ames
Ames, Iowa, 50010
Community Hospital of Anaconda
Anaconda, Montana, 59711
Cancer Care Center at Island Hospital
Anacortes, Washington, 98221
Kaiser Permanente-Anaheim
Anaheim, California, 92806
Anchorage Associates in Radiation Medicine
Anchorage, Alaska, 98508
Anchorage Radiation Therapy Center
Anchorage, Alaska, 99504
Alaska Breast Care and Surgery LLC
Anchorage, Alaska, 99508
Alaska Oncology and Hematology LLC
Anchorage, Alaska, 99508
Alaska Regional Hospital
Anchorage, Alaska, 99508
Alaska Women's Cancer Care
Anchorage, Alaska, 99508
Anchorage Oncology Centre
Anchorage, Alaska, 99508
Katmai Oncology Group
Anchorage, Alaska, 99508
Providence Alaska Medical Center
Anchorage, Alaska, 99508
AnMed Health Cancer Center
Anderson, South Carolina, 29621
Saint Joseph Mercy Hospital
Ann Arbor, Michigan, 48106
University of Michigan Comprehensive Cancer Center
Ann Arbor, Michigan, 48109
Anne Arundel Medical Center
Annapolis, Maryland, 21401
Langlade Hospital and Cancer Center
Antigo, Wisconsin, 54409
Kaiser Permanente-Deer Valley Medical Center
Antioch, California, 94531
Fox Valley Surgical Associates Limited
Appleton, Wisconsin, 54911
ThedaCare Regional Cancer Center
Appleton, Wisconsin, 54911
ThedaCare Regional Medical Center - Appleton
Appleton, Wisconsin, 54911
Ascension Saint Elizabeth Hospital
Appleton, Wisconsin, 54915
Mission Hope Medical Oncology - Arroyo Grande
Arroyo Grande, California, 93420
PCR Oncology
Arroyo Grande, California, 93420
Randolph Hospital
Asheboro, North Carolina, 27203
Mission Hospital
Asheville, North Carolina, 28801
AdventHealth Infusion Center Asheville
Asheville, North Carolina, 28803
Messino Cancer Centers
Asheville, North Carolina, 28806
King's Daughter's Medical Center
Ashland, Kentucky, 41101
Duluth Clinic Ashland
Ashland, Wisconsin, 54806
Northwest Wisconsin Cancer Center
Ashland, Wisconsin, 54806
University Cancer and Blood Center LLC
Athens, Georgia, 30607
Emory University Hospital Midtown
Atlanta, Georgia, 30308
Emory University Hospital/Winship Cancer Institute
Atlanta, Georgia, 30322
Emory Saint Joseph's Hospital
Atlanta, Georgia, 30342
Northside Hospital
Atlanta, Georgia, 30342
Sutter Auburn Faith Hospital
Auburn, California, 95602
Sutter Cancer Centers Radiation Oncology Services-Auburn
Auburn, California, 95603
Hematology Oncology Associates of Central New York-Auburn
Auburn, New York, 13021
MultiCare Auburn Medical Center
Auburn, Washington, 98001
Augusta University Medical Center
Augusta, Georgia, 30912
Harold Alfond Center for Cancer Care
Augusta, Maine, 04330
Rocky Mountain Cancer Centers-Aurora
Aurora, Colorado, 80012
The Medical Center of Aurora
Aurora, Colorado, 80012
Rocky Mountain Regional VA Medical Center
Aurora, Colorado, 80045
University of Colorado Hospital
Aurora, Colorado, 80045
Rush - Copley Medical Center
Aurora, Illinois, 60504
Dell Seton Medical Center at The University of Texas
Austin, Texas, 78701
Mount Sinai Comprehensive Cancer Center at Aventura
Aventura, Florida, 33180
Virginia Mason Bainbridge Island Medical Center
Bainbridge Island, Washington, 98110
Saint Alphonsus Medical Center-Baker City
Baker City, Oregon, 97814
AIS Cancer Center at San Joaquin Community Hospital
Bakersfield, California, 93301
Kaiser Permanente-Baldwin Park
Baldwin Park, California, 91706
University of Maryland/Greenebaum Cancer Center
Baltimore, Maryland, 21201
Greater Baltimore Medical Center
Baltimore, Maryland, 21204
Sinai Hospital of Baltimore
Baltimore, Maryland, 21215
MedStar Union Memorial Hospital
Baltimore, Maryland, 21218
MedStar Harbor Hospital
Baltimore, Maryland, 21225
MedStar Franklin Square Medical Center/Weinberg Cancer Institute
Baltimore, Maryland, 21237
Kaiser Permanente-Woodlawn Medical Center
Baltimore, Maryland, 21244
Johns Hopkins University/Sidney Kimmel Cancer Center
Baltimore, Maryland, 21287
Eastern Maine Medical Center
Bangor, Maine, 04401
Flaget Memorial Hospital
Bardstown, Kentucky, 40004
Advocate Good Shepherd Hospital
Barrington, Illinois, 60010
Memorial Sloan Kettering Basking Ridge
Basking Ridge, New Jersey, 07920
LSU Health Baton Rouge-North Clinic
Baton Rouge, Louisiana, 70805
Our Lady of The Lake
Baton Rouge, Louisiana, 70808
Louisiana Hematology Oncology Associates LLC
Baton Rouge, Louisiana, 70809
Mary Bird Perkins Cancer Center
Baton Rouge, Louisiana, 70809
Ochsner Health Center-Summa
Baton Rouge, Louisiana, 70809
Our Lady of the Lake Physicians Group - Medical Oncology
Baton Rouge, Louisiana, 70809
Medical Center of Baton Rouge
Baton Rouge, Louisiana, 70816
Ochsner High Grove
Baton Rouge, Louisiana, 70836
Bronson Battle Creek
Battle Creek, Michigan, 49017
Essentia Health - Baxter Clinic
Baxter, Minnesota, 56425
Northwell Health Imbert Cancer Center
Bay Shore, New York, 11706
Houston Methodist San Jacinto Hospital
Baytown, Texas, 77521
UHHS-Chagrin Highlands Medical Center
Beachwood, Ohio, 44122
UPMC-Heritage Valley Health System Beaver
Beaver, Pennsylvania, 15009
Indu and Raj Soin Medical Center
Beavercreek, Ohio, 45431
UM Upper Chesapeake Medical Center
Bel Air, Maryland, 21014
Waldo County General Hospital
Belfast, Maine, 04915
Nebraska Medicine-Bellevue
Bellevue, Nebraska, 68123
Overlake Medical Center
Bellevue, Washington, 98004
Swedish Cancer Institute-Eastside Oncology Hematology
Bellevue, Washington, 98005
Kaiser Permanente-Bellflower
Bellflower, California, 90706
PeaceHealth Saint Joseph Medical Center
Bellingham, Washington, 98225
Gaston Hematology and Oncology Associates-Belmont
Belmont, North Carolina, 28012
Strecker Cancer Center-Belpre
Belpre, Ohio, 45714
Sanford Joe Lueken Cancer Center
Bemidji, Minnesota, 56601
Saint Charles Health System
Bend, Oregon, 97701
Southwestern Vermont Medical Center
Bennington, Vermont, 05201
Alta Bates Summit Medical Center-Herrick Campus
Berkeley, California, 94704
Central Vermont Medical Center/National Life Cancer Treatment
Berlin Corners, Vermont, 05602
Walter Reed National Military Medical Center
Bethesda, Maryland, 20889-5600
Saint Luke's University Hospital-Bethlehem Campus
Bethlehem, Pennsylvania, 18015
Lehigh Valley Hospital - Muhlenberg
Bethlehem, Pennsylvania, 18017
University of Iowa Healthcare Cancer Services Quad Cities
Bettendorf, Iowa, 52722
Beverly Hospital
Beverly, Massachusetts, 01915
MaineHealth/SMHC Cancer Care and Blood Disorders-Biddeford
Biddeford, Maine, 04005
Billings Clinic Cancer Center
Billings, Montana, 59101
Saint Vincent Healthcare
Billings, Montana, 59101
Saint Vincent Frontier Cancer Center
Billings, Montana, 59102
University of Alabama at Birmingham Cancer Center
Birmingham, Alabama, 35233
Sanford Bismarck Medical Center
Bismarck, North Dakota, 58501
Saint Joseph Medical Center
Bloomington, Illinois, 61701
Illinois CancerCare-Bloomington
Bloomington, Illinois, 61704
Saint Joseph's/Candler - Bluffton Campus
Bluffton, South Carolina, 29910
Saint Elizabeth Boardman Hospital
Boardman, Ohio, 44512
Boca Raton Regional Hospital
Boca Raton, Florida, 33486
Prisma Health Cancer Institute - Spartanburg
Boiling Springs, South Carolina, 29316
Saint Alphonsus Cancer Care Center-Boise
Boise, Idaho, 83706
Saint Luke's Cancer Institute - Boise
Boise, Idaho, 83712
Central Care Cancer Center - Bolivar
Bolivar, Missouri, 65613
Parkland Health Center-Bonne Terre
Bonne Terre, Missouri, 63628
McFarland Clinic PC-Boone
Boone, Iowa, 50036
Massachusetts General Hospital Cancer Center
Boston, Massachusetts, 02114
Brigham and Women's Hospital
Boston, Massachusetts, 02115
Boston Medical Center
Boston, Massachusetts, 02118
Beth Israel Deaconess Medical Center
Boston, Massachusetts, 02215
Dana-Farber Cancer Institute
Boston, Massachusetts, 02215
Boulder Community Hospital
Boulder, Colorado, 80301
Boulder Community Foothills Hospital
Boulder, Colorado, 80303
Rocky Mountain Cancer Centers-Boulder
Boulder, Colorado, 80304
Bozeman Deaconess Hospital
Bozeman, Montana, 59715
Essentia Health Saint Joseph's Medical Center
Brainerd, Minnesota, 56401
Cox Cancer Center Branson
Branson, Missouri, 65616
Northeast Georgia Medical Center Braselton
Braselton, Georgia, 30517
Harrison HealthPartners Hematology and Oncology-Bremerton
Bremerton, Washington, 98310
Harrison Medical Center
Bremerton, Washington, 98310
Lafayette Family Cancer Center-EMMC
Brewer, Maine, 04412
Ocean University Medical Center
Brick, New Jersey, 08724
United Hospital Center
Bridgeport, West Virginia, 26330
Steward Saint Elizabeth's Medical Center
Brighton, Massachusetts, 02135
Saint Joseph Mercy Brighton
Brighton, Michigan, 48114
Trinity Health IHA Medical Group Hematology Oncology - Brighton
Brighton, Michigan, 48114
Bristol Regional Medical Center
Bristol, Tennessee, 37620
Wellmont Medical Associates Oncology and Hematology-Bristol
Bristol, Tennessee, 37620
Wellmont Medical Associates-Bristol
Bristol, Virginia, 24201
Ascension Southeast Wisconsin Hospital - Elmbrook Campus
Brookfield, Wisconsin, 53045
State University of New York Downstate Medical Center
Brooklyn, New York, 11203
Veteran Affairs New York Harbor Healthcare System-Brooklyn Campus
Brooklyn, New York, 11209
New York-Presbyterian/Brooklyn Methodist Hospital
Brooklyn, New York, 11215
Maimonides Medical Center
Brooklyn, New York, 11219
Crozer-Keystone Regional Cancer Center at Broomall
Broomall, Pennsylvania, 19008
Henry Ford Cancer Institute-Downriver
Brownstown, Michigan, 48183
Saint Joseph Regional Cancer Center
Bryan, Texas, 77802
Bryn Mawr Hospital
Bryn Mawr, Pennsylvania, 19010
Roswell Park Cancer Institute
Buffalo, New York, 14263
Providence Saint Joseph Medical Center/Disney Family Cancer Center
Burbank, California, 91505
Highline Medical Center-Main Campus
Burien, Washington, 98166
Kaiser Permanente-Burke Medical Center
Burke, Virginia, 22015
Mills-Peninsula Medical Center
Burlingame, California, 94010
Lahey Hospital and Medical Center
Burlington, Massachusetts, 01805
Cone Health Cancer Center at Alamance Regional
Burlington, North Carolina, 27215
University of Vermont Medical Center
Burlington, Vermont, 05401
University of Vermont and State Agricultural College
Burlington, Vermont, 05405
Aurora Cancer Care-Southern Lakes VLCC
Burlington, Wisconsin, 53105
Fairview Ridges Hospital
Burnsville, Minnesota, 55337
Minnesota Oncology - Burnsville
Burnsville, Minnesota, 55337
UPMC Hillman Cancer Center at Butler Health System
Butler, Pennsylvania, 16001
Saint James Community Hospital and Cancer Treatment Center
Butte, Montana, 59701
Saint Alphonsus Cancer Care Center-Caldwell
Caldwell, Idaho, 83605
Cambridge Medical Center
Cambridge, Minnesota, 55008
Cooper Hospital University Medical Center
Camden, New Jersey, 08103
Sutter Cancer Centers Radiation Oncology Services-Cameron Park
Cameron Park, California, 95682
UPMC Camp Hill
Camp Hill, Pennsylvania, 17011
Sands Cancer Center
Canandaigua, New York, 14424
Illinois CancerCare-Canton
Canton, Illinois, 61520
Saint Joseph Mercy Canton
Canton, Michigan, 48188
Trinity Health IHA Medical Group Hematology Oncology - Canton
Canton, Michigan, 48188
Cleveland Clinic Mercy Hospital
Canton, Ohio, 44708
Aultman Health Foundation
Canton, Ohio, 44710
Saint Francis Medical Center
Cape Girardeau, Missouri, 63703
Southeast Cancer Center
Cape Girardeau, Missouri, 63703
Memorial Hospital of Carbondale
Carbondale, Illinois, 62902
Carlisle Regional Cancer Center
Carlisle, Pennsylvania, 17015
Mercy Cancer Center �� Carmichael
Carmichael, California, 95608
Mercy San Juan Medical Center
Carmichael, California, 95608
Caro Cancer Center
Caro, Michigan, 48723
Saint Anthony Regional Hospital
Carroll, Iowa, 51401
Carson Tahoe Regional Medical Center
Carson City, Nevada, 89703
SIH Cancer Institute
Carterville, Illinois, 62918
Illinois CancerCare-Carthage
Carthage, Illinois, 62321
Eden Hospital Medical Center
Castro Valley, California, 94546
Sandra L Maxwell Cancer Center
Cedar City, Utah, 84720
Physicians' Clinic of Iowa PC
Cedar Rapids, Iowa, 52402
Mercy Hospital
Cedar Rapids, Iowa, 52403
Oncology Associates at Mercy Medical Center
Cedar Rapids, Iowa, 52403
AdventHealth Celebration
Celebration, Florida, 34747
Rocky Mountain Cancer Centers - Centennial
Centennial, Colorado, 80112
Dayton Physicians LLC-Miami Valley South
Centerville, Ohio, 45459
Miami Valley Hospital South
Centerville, Ohio, 45459
Centralia Oncology Clinic
Centralia, Illinois, 62801
Providence Regional Cancer System-Centralia
Centralia, Washington, 98531
Christiana Care Health System-Concord Health Center
Chadds Ford, Pennsylvania, 19317
Chambersburg Hospital
Chambersburg, Pennsylvania, 17201
WellSpan Medical Oncology and Hematology
Chambersburg, Pennsylvania, 17201
Cancer Center of Kansas - Chanute
Chanute, Kansas, 66720
UNC Lineberger Comprehensive Cancer Center
Chapel Hill, North Carolina, 27599
Geauga Hospital
Chardon, Ohio, 44024
Roper Hospital
Charleston, South Carolina, 29401
Charleston Oncology - Roper
Charleston, South Carolina, 29403
Lowcountry Hematology Oncology PA-North Charleston
Charleston, South Carolina, 29406
Bon Secours Saint Francis Hospital
Charleston, South Carolina, 29414
Charleston Oncology - Saint Francis
Charleston, South Carolina, 29414
Lowcountry Hematology Oncology PA-West Ashley
Charleston, South Carolina, 29414
Medical University of South Carolina
Charleston, South Carolina, 29425
West Virginia University Charleston Division
Charleston, West Virginia, 25304
Novant Health Presbyterian Medical Center
Charlotte, North Carolina, 28204
Novant Health Carolina Surgical - Randolph
Charlotte, North Carolina, 28207
Oncology Specialists of Charlotte
Charlotte, North Carolina, 28207
Southern Oncology Specialists-Charlotte
Charlotte, North Carolina, 28262
Sentara Martha Jefferson Hospital
Charlottesville, Virginia, 22901
University of Virginia Cancer Center
Charlottesville, Virginia, 22908
Memorial Hospital
Chattanooga, Tennessee, 37404
Saint Joseph Mercy Chelsea
Chelsea, Michigan, 48118
Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital
Chelsea, Michigan, 48118
Saint Luke's Hospital
Chesterfield, Missouri, 63017
Cheyenne Regional Medical Center-West
Cheyenne, Wyoming, 82001
Mount Sinai Hospital Medical Center
Chicago, Illinois, 60608
Northwestern University
Chicago, Illinois, 60611
John H Stroger Jr Hospital of Cook County
Chicago, Illinois, 60612
Rush University Medical Center
Chicago, Illinois, 60612
University of Illinois
Chicago, Illinois, 60612
Swedish Covenant Hospital
Chicago, Illinois, 60625
Presence Resurrection Medical Center
Chicago, Illinois, 60631
University of Chicago Comprehensive Cancer Center
Chicago, Illinois, 60637
Advocate Illinois Masonic Medical Center
Chicago, Illinois, 60657
Adena Regional Medical Center
Chillicothe, Ohio, 45601
Ascension Calumet Hospital
Chilton, Wisconsin, 53014
Marshfield Clinic-Chippewa Center
Chippewa Falls, Wisconsin, 54729
Oncology Hematology Care Inc-Eden Park
Cincinnati, Ohio, 45202
Oncology Hematology Care Inc-Mercy West
Cincinnati, Ohio, 45211
University of Cincinnati Cancer Center-UC Medical Center
Cincinnati, Ohio, 45219
Good Samaritan Hospital - Cincinnati
Cincinnati, Ohio, 45220
Oncology Hematology Care Inc-Anderson
Cincinnati, Ohio, 45230
Oncology Hematology Care Inc-Kenwood
Cincinnati, Ohio, 45236
Bethesda North Hospital
Cincinnati, Ohio, 45242
Oncology Hematology Care Inc-Blue Ash
Cincinnati, Ohio, 45242
TriHealth Cancer Institute-Westside
Cincinnati, Ohio, 45247
TriHealth Cancer Institute-Anderson
Cincinnati, Ohio, 45255
Siteman Cancer Center at Saint Peters Hospital
City of Saint Peters, Missouri, 63376
Clackamas Radiation Oncology Center
Clackamas, Oregon, 97015
Providence Cancer Institute Clackamas Clinic
Clackamas, Oregon, 97015
Hematology Oncology Consultants-Clarkston
Clarkston, Michigan, 48346
Newland Medical Associates-Clarkston
Clarkston, Michigan, 48346
Wake Forest University at Clemmons
Clemmons, North Carolina, 27012
Case Western Reserve University
Cleveland, Ohio, 44106
MetroHealth Medical Center
Cleveland, Ohio, 44109
Cleveland Clinic Cancer Center/Fairview Hospital
Cleveland, Ohio, 44111
Cleveland Clinic Foundation
Cleveland, Ohio, 44195
Southeastern Medical Oncology Center-Clinton
Clinton, North Carolina, 28328
Henry Ford Macomb Hospital-Clinton Township
Clinton Township, Michigan, 48038
Medical Oncology and Hematology Associates-West Des Moines
Clive, Iowa, 50325
Mercy Cancer Center-West Lakes
Clive, Iowa, 50325
Community Cancer Institute
Clovis, California, 93611
University Oncology Associates
Clovis, California, 93611
AdventHealth Infusion Center Haywood
Clyde, North Carolina, 28721
Big Horn Basin Cancer Center
Cody, Wyoming, 82414
Billings Clinic-Cody
Cody, Wyoming, 82414
Kootenai Health - Coeur d'Alene
Coeur d'Alene, Idaho, 83814
Main Line Health Center-Collegeville
Collegeville, Pennsylvania, 19426
Penrose-Saint Francis Healthcare
Colorado Springs, Colorado, 80907
Rocky Mountain Cancer Centers-Penrose
Colorado Springs, Colorado, 80907
UCHealth Memorial Hospital Central
Colorado Springs, Colorado, 80909
Memorial Hospital North
Colorado Springs, Colorado, 80920
Saint Francis Cancer Center
Colorado Springs, Colorado, 80923
University of Missouri - Ellis Fischel
Columbia, Missouri, 65212
Puerto Rico4 sites
Cancer Center-Metro Medical Center Bayamon
Bayamón, 00959-5060
Doctors Cancer Center
Manati, 00674
San Juan Community Oncology Group
San Juan, 00917
San Juan City Hospital
San Juan, 00936
About this study
Official title: A Randomized Phase III Trial for Surgically Resected Early Stage Non-small Cell Lung Cancer: Crizotinib Versus Observation for Patients With Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein
This randomized phase III trial studies how well crizotinib works in treating patients with stage IB-IIIA non-small cell lung cancer that has been removed by surgery and has a mutation in a protein called anaplastic lymphoma kinase (ALK). Mutations, or changes, in ALK can make it very active and important for tumor cell growth and progression. Crizotinib may stop the growth of tumor cells by blocking the ALK protein from working. Crizotinib may be an effective treatment for patients with non-small cell lung cancer and an ALK fusion mutation.
Read the detailed description
PRIMARY OBJECTIVES:
- To evaluate whether adjuvant therapy with crizotinib will result in improved overall survival (OS) for patients with stage IB >= 4 cm, II and IIIA, ALK-positive non-small cell lung cancer (NSCLC) following surgical resection.
SECONDARY OBJECTIVES:
- To evaluate and compare disease-free survival (DFS) associated with crizotinib.
II. To evaluate the safety profile of crizotinib when given in the adjuvant therapy setting.
III. To collect tumor tissue and blood specimens for future research.
OUTLINE: Patients are randomized to 1 of 2 treatment arms.
ARM A: Patients receive crizotinib orally (PO) twice daily (BID) on days 1-21. Treatment repeats every 21 days for up to 2 years in the absence of disease progression or unacceptable toxicity.
ARM B: Patients undergo observation.
After completion of study treatment, patients are followed up every 6 months if < 4 or 5 years from study entry, and every 12 months if 5-10 or 6-10 years from study entry.
- Conditions
- ALK Gene Rearrangement, ALK Gene Translocation, ALK Positive, Stage IB Non-Small Cell Lung Carcinoma AJCC v7, Stage II Non-Small Cell Lung Cancer AJCC v7, Stage IIA Non-Small Cell Lung Carcinoma AJCC v7
- Being tested
- Clinical Observation, Crizotinib, Laboratory Biomarker Analysis
- Medical subject headings
- Carcinoma, Non-Small-Cell Lung
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Clinical ObservationOther
Undergo observation
CrizotinibDrug
Also called MET tyrosine kinase inhibitor PF-02341066, PF-02341066, PF-2341066, Xalkori
Given PO
Laboratory Biomarker AnalysisOther
Correlative studies
| Study group | Role | What they receive |
|---|---|---|
| Arm A (crizotinib) | Experimental | Patients receive crizotinib PO BID on days 1-21. Treatment repeats every 21 days for up to 2 years in the absence of disease progression or unacceptable toxicity. Receives: Drug: Crizotinib; Other: Laboratory Biomarker Analysis |
| Arm B (observation) | Active comparator | Patients undergo observation. Receives: Other: Clinical Observation; Other: Laboratory Biomarker Analysis |
What is being measured
The primary outcome is the main question the study is designed to answer.
Overall survival (OS)
Distribution will be estimated using the Kaplan-Meier method, and Cox proportional hazards models will be used to estimate the treatment hazard ratios. The primary comparison will use a logrank test stratified on the randomization stratification factors with a one-sided type I error rate of 5%. Other comparisons of groups will be made using the logrank test and Cox modeling. Estimate will be accompanied by the corresponding 90% confidence intervals.
Measured: The time from randomization to death from any cause, assessed up to 10 years
Secondary outcomes (2)
Disease free survival (DFS)
Distribution will be estimated using the Kaplan-Meier method, and Cox proportional hazards models will be used to estimate the treatment hazard ratios. Estimate will be accompanied by the corresponding 90% confidence intervals.
Measured: The time from randomization to the earliest event defined as: disease recurrence confirmed by biopsy, any new lung cancer (even in the opposite lung) confirmed by biopsy, or death from any cause at any known point in time, assessed up to 10 years
Toxicity rates, determined using the Common Terminology Criteria for Adverse Events (CTCAE) version 4.0
Toxicity rates will be compared using Fisher?s exact tests with a one-sided type I error rate of 5%; multivariable logistic regression modeling will be used to adjust for the effect of any covariates that are associated with these categorical outcomes.
Measured: Up to 10 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted28 Jul 2014 (estimated)
- Study start23 Mar 2015
- Primary completion1 May 2036 (estimated)
- Study completion1 May 2036 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for ALK Gene RearrangementStudies of the same condition, open and under way.
- More trials run by ECOG-ACRIN Cancer Research GroupThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 3
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 166 participants (actual)
Sponsor and investigators
- Lead sponsor
- ECOG-ACRIN Cancer Research Group
- Sponsor type
- Research network
- Collaborators
- National Cancer Institute (NCI)
- Responsible party
- Sponsor
- Investigators
- David Gerber, Principal investigator, ECOG-ACRIN Cancer Research Group
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02201992
- Sponsor's protocol ID
- E4512
- Other IDs
- NCI-2014-01507, s16-02072, E4512, E4512, U10CA180820, U10CA180830, U10CA021115, U24CA196172
- Status last verified
- Dec 2025
- First submitted
- 21 Jul 2014
- Last updated
- 19 Dec 2025
- Results posted
- No
- Data monitoring committee
- No
Publications
Gerber DE, Wang Y, Langer CJ, Khullar OV, Kozono DE, Cornelius LA, Forde PM, Nwaneri MO, Neal JW, Talsania A, Leal TA, Patel M, Donthireddy KR, Waqar SN, Chaft JE, Govindan R, Sands JM, Malik S, Li T, Sun Z, Stinchcombe TE, Vokes EE, Mandrekar SJ, Oxnard GR, Carbone DP, Ramalingam SS. Crizotinib versus observation or placebo for surgically resected early-stage ALK-positive non-small-cell lung cancer (Eastern Cooperative Oncology Group-American College of Radiology Imaging Network E4512): a phase 3 trial. Lancet Respir Med. 2026 Aug 25:S2213-2600(26)00192-X. doi: 10.1016/S2213-2600(26)00192-X. Online ahead of print.
PubMed 42641639
Study at a glance
From the registry record, last updated by the sponsor on 19 Dec 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Randomized Phase III Trial for Surgically Resected Early Stage Non-small Cell Lung Cancer: Crizotinib Versus Observation for Patients With Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein
- ClinicalTrials.gov ID
- NCT02201992
- Acronym / sponsor ID
- E4512
- Conditions
- ALK Gene Rearrangement, ALK Gene Translocation, ALK Positive, Stage IB Non-Small Cell Lung Carcinoma AJCC v7, Stage II Non-Small Cell Lung Cancer AJCC v7, Stage IIA Non-Small Cell Lung Carcinoma AJCC v7
- Phase
- Phase 3
- Study type
- Interventional
- Recruitment status
- Active, not recruiting
- Enrolment
- 166 participants (actual)
- Lead sponsor
- ECOG-ACRIN Cancer Research GroupResearch network
- Collaborators
- National Cancer Institute (NCI)
- Study start
- 23 Mar 2015 (actual)
- Primary completion
- 1 May 2036 (estimated)
- Study completion
- 1 May 2036 (estimated)
- First posted
- 28 Jul 2014 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This randomized phase III trial studies how well crizotinib works in treating patients with stage IB-IIIA non-small cell lung cancer that has been removed by surgery and has a mutation in a protein called anaplastic lymphoma kinase (ALK). Mutations, or changes, in ALK can make it very active and important for tumor cell growth and progression. Crizotinib may stop the growth of tumor cells by blocking the ALK protein from working. Crizotinib may be an effective treatment for patients with non-small cell lung cancer and an ALK fusion mutation.
Detailed description
PRIMARY OBJECTIVES:
- To evaluate whether adjuvant therapy with crizotinib will result in improved overall survival (OS) for patients with stage IB >= 4 cm, II and IIIA, ALK-positive non-small cell lung cancer (NSCLC) following surgical resection.
SECONDARY OBJECTIVES:
- To evaluate and compare disease-free survival (DFS) associated with crizotinib.
II. To evaluate the safety profile of crizotinib when given in the adjuvant therapy setting.
III. To collect tumor tissue and blood specimens for future research.
OUTLINE: Patients are randomized to 1 of 2 treatment arms.
ARM A: Patients receive crizotinib orally (PO) twice daily (BID) on days 1-21. Treatment repeats every 21 days for up to 2 years in the absence of disease progression or unacceptable toxicity.
ARM B: Patients undergo observation.
After completion of study treatment, patients are followed up every 6 months if < 4 or 5 years from study entry, and every 12 months if 5-10 or 6-10 years from study entry.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Arm A (crizotinib) | Experimental | Drug: Crizotinib, Other: Laboratory Biomarker AnalysisPatients receive crizotinib PO BID on days 1-21. Treatment repeats every 21 days for up to 2 years in the absence of disease progression or unacceptable toxicity. |
| Arm B (observation) | Active comparator | Other: Clinical Observation, Other: Laboratory Biomarker AnalysisPatients undergo observation. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (33 listed)
- Patients must have undergone complete surgical resection of their stage IB (>= 4 cm), II, or non-squamous IIIA NSCLC per American Joint Committee on Cancer (AJCC) 7th edition and have had negative margins; N3 disease is not allowed
- Baseline chest computed tomography (CT) with or without contrast must be performed within 6 months (180 days) prior to randomization to ensure no evidence of disease; if clinically indicated additional imaging studies must be performed to rule out metastatic disease
- Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1
- Patients must be registered to the ALCHEMIST-SCREEN (ALLIANCE A151216) trial prior to randomization
- Positive for translocation or inversion events involving the ALK gene locus (e.g. resulting in echinoderm microtubule associated protein like 4 [EML4]-ALK fusion) as determined by the Vysis Break Point fluorescence in situ hybridization (FISH) assay and defined by an increase in the distance between 5? and 3? ALK probes or the loss of the 5? probe; this must have been performed:
Key exclusion criteria (0 listed)
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Clinical ObservationUndergo observation | Other | Arm B (observation) |
| CrizotinibAlso: MET tyrosine kinase inhibitor PF-02341066, PF-02341066, PF-2341066, XalkoriGiven PO | Drug | Arm A (crizotinib) |
| Laboratory Biomarker AnalysisCorrelative studies | Other | Arm A (crizotinib), Arm B (observation) |
Primary outcome
Overall survival (OS)
Time frame: The time from randomization to death from any cause, assessed up to 10 years
Distribution will be estimated using the Kaplan-Meier method, and Cox proportional hazards models will be used to estimate the treatment hazard ratios. The primary comparison will use a logrank test stratified on the randomization stratification factors with a one-sided type I error rate of 5%. Other comparisons of groups will be made using the logrank test and Cox modeling. Estimate will be accompanied by the corresponding 90% confidence intervals.
2 secondary outcomes
Disease free survival (DFS)
Time frame: The time from randomization to the earliest event defined as: disease recurrence confirmed by biopsy, any new lung cancer (even in the opposite lung) confirmed by biopsy, or death from any cause at any known point in time, assessed up to 10 years
Toxicity rates, determined using the Common Terminology Criteria for Adverse Events (CTCAE) version 4.0
Time frame: Up to 10 years
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 19 Dec 2025.
- Derived from this study: PubMed 42641639Gerber DE, Wang Y, Langer CJ, Khullar OV, Kozono DE, Cornelius LA, Forde PM, Nwaneri MO, Neal JW, Talsania A, Leal TA, Patel M, Donthireddy KR, Waqar SN, Chaft JE, Govindan R, Sands JM, Malik S, Li T, Sun Z, Stinchcombe TE, Vokes EE, Mandrekar SJ, Oxnard GR, Carbone DP, Ramalingam SS. Crizotinib versus observation or placebo for surgically resected early-stage ALK-positive non-small-cell lung cancer (Eastern Cooperative Oncology Group-American College of Radiology Imaging Network E4512): a phase 3 trial. Lancet Respir Med. 2026 Aug 25:S2213-2600(26)00192-X. doi: 10.1016/S2213-2600(26)00192-X. Online ahead of print.
Related trials for ALK Gene Rearrangement
Active, not recruitingPhase 2
Nivolumab With or Without Varlilumab in Treating Patients With Relapsed or Refractory Aggressive B-cell Lymphomas
ALK-Positive Large B-Cell Lymphoma, Diffuse Large B-Cell Lymphoma Activated B-Cell Type
RecruitingPhase 1
A Study of Gilteritinib in Adults With Advanced ALK-positive Non-small Cell Lung Cancer (NSCLC)
Non-small Cell Lung Cancer (NSCLC), Anaplastic Lymphoma Kinase (ALK) Positive
RecruitingObservational study
Efficacy and Safety of Ivonescimab Monotherapy as First-Line Treatment for PD-L1-Positive, Driver Gene-Negative, Locally Advanced or Metastatic NSCLC: A Multicenter, Prospective, Real-World Cohort Study
Patients Must Have Histologically or Cytologically Confirmed Locally Advanced or Metastatic NSCLC, EGFR Mutation-negative and ALK Rearrangement-negative
RecruitingPhase 2
Golcadomide and Rituximab as Bridging Therapy for Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma Before CAR T-cell Therapy
Large B-Cell Lymphoma With IRF4 Rearrangement, Recurrent Aggressive B-Cell Non-Hodgkin Lymphoma
Active, not recruitingPhase 1/2
Polatuzumab Vedotin and Combination Chemotherapy With or Without Glofitamab for the Treatment of Untreated Aggressive Large B-cell Lymphoma
Aggressive Non-Hodgkin Lymphoma, ALK-Positive Large B-Cell Lymphoma
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
David Gerber principal investigator
ECOG-ACRIN Cancer Research Group
1,618 sites in 3 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 3 study testing Clinical Observation, Crizotinib and Laboratory Biomarker Analysis in people with ALK Gene Rearrangement and ALK Gene Translocation, run by ECOG-ACRIN Cancer Research Group at 1,618 sites in 3 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 33 inclusion and 0 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: under way, not looking for participants, as of the sponsor's last update on 19 Dec 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1,618 sites in United States, Puerto Rico, Guam. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Overall survival (OS) (time frame: The time from randomization to death from any cause, assessed up to 10 years). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT02201992, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 19 Dec 2025.